Beijing Silian Pharmaceutical Co., Ltd., a subsidiary of Chuangying Group, is a major supplier of folic acid tablets for the prevention of fetal malformations in China, and a comprehensive pharmaceutical high-tech enterprise with R&D/production/sales capabilities
Beijing Silian Pharmaceutical Co., Ltd. is a comprehensive pharmaceutical enterprise integrating R&D, production and marketing, the largest manufacturing enterprise in the field of folic acid in China, and a national high-tech enterprise. Beijing Silian Pharmaceutical Co., Ltd. was initiated and established by Beijing Chuangying Technology Industry Group, covering reproductive health, maternal and child health care, orthopedics, oncology, gynecology, pediatrics, geriatrics and many other fields, now the company is headquartered in Beijing Economic and Technological Development Zone, business in more than 340 cities in 26 provinces across the country.
With the concept of "building maternal and child health", Beijing Silian Pharmaceutical Co., Ltd. focuses on the field of big health. The company's core variety 'Silian folic acid tablets' is mainly used to prevent birth defects such as neural tube defects, which is the result of scientific research achieved by the cooperation of the Chinese and American governments for 13 years, costing 20 million US dollars and 250,000 cases of clinical observation. The results have been adopted by more than 50 countries around the world, and have been published in the Lancet, New England Journal of Medicine, Chinese Medical Journal, Chinese Journal of Epidemiology and other well-known peer-reviewed journals at home and abroad. In 1997, the company proposed that the quality standard of 0.4mg folic acid was set as an international standard by the World Health Organization and included in the Chinese Pharmacopoeia. In the same year, "Silian Folic Acid Tablets" was awarded the new drug certificate by the Ministry of Health, and was promoted to the whole country by the Ministry of Health of China as a key project of "100 scientific and technological achievements in 10 years", and in 2003, it was jointly issued by the Ministry of Science and Technology and other ministries and bureaus, and was rated as "National Key New Product" by the Ministry of Science and Technology, the Ministry of Commerce and other five ministries and commissions.
The company adheres to the road of scientific and technological innovation to rejuvenate the enterprise, increases R&D investment, enhances independent innovation capabilities, and gradually forms independent intellectual property rights and core technologies for R&D results. At present, a number of Class 1 and Class 3 new drugs such as "Echinacoside Tablets", a new class of drugs for the prevention of Alzheimer's disease, have been successfully developed. The company also has a large number of health foods such as Kingsleyan calcium in the first trimester, second and third trimester and pregnant women. As well as new products suitable for women of childbearing age and pregnant mothers, including DHA algal oil milk calcium powder and pregnant women's toothpaste, special shampoo and shower gel for pregnant women taken by hundreds of millions of mothers during pregnancy. At present, the company has obtained more than 30 invention patents and nearly 100 utility model and design patents. It has a series of nearly 1,000 registered trademarks with "Silian" and "Kingslian" as the main trademarks.
In 2013, based on the long-term development strategy of the enterprise, Beijing Silian Pharmaceutical Co., Ltd. built a new factory in Daxing Biomedical Industry Base (Zhongguancun Science and Technology Park) in order to improve the process level and product quality, with a total planned land area of about 200 acres. The first phase of the production base, which covers an area of 38 acres and invests more than 300 million yuan, has been completed and successfully passed the GMP certification. Beijing Silian Pharmaceutical Co., Ltd. Cangzhou API base plans to use 242 acres of land, has started construction in July 16, and is expected to be completed and put into production by the end of 16.
